ReviewThe Lancet regional health. Western Pacific2026
China's nationwide antimicrobial resistance surveillance networks: a systematic analysis from One Health perspective.
Review in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses a growing threat to human, animal, and environmental health, necessitating integrated surveillance systems to effectively address this challenge. Globally, many countries have committed to expanding AMR monitoring under their national action plans, yet the development and alignment of surveillance systems across different sectors remain insufficiently documented, likewise in China with rapid economic transformation and severe health challenges. Using the EPI-Net One Health reporting guideline, we reviewed 13 nationwide AMR surveillance networks in China. The findings demonstrate notable progress in sector-specific surveillance, particularly within human and animal sector. However, gaps persist in environmental monitoring, cross-sector integration, methodological standardization, and data sharing, which constrain the generation of high-quality, comprehensive AMR data. These findings highlight the urgent need for increased investment in advanced technologies like whole-genome sequencing (WGS), alongside broader stakeholder engagement and clearer consensus on data governance and data-sharing mechanisms to strengthen AMR surveillance from One Health perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.